FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

The FDA has approved the first-in-class RAS inhibitor for metastatic pancreatic cancer, offering a new targeted treatment option for patients with this aggressive cancer type.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.